Poster Session B
Monday, January 13, 2020
5:15 p.m.–7:15 p.m.

B01 Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC. Franziska Haderk, University of California San Francisco, San Francisco, CA, USA.

B02 The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Milica Momcilovic, University of California Los Angeles, Los Angeles, CA, USA.

B03 JNJ-61186372, an Fc effector enhanced EGFR/cMet bispecific antibody, induces EGFR/cMet downmodulation and efficacy through monocyte and macrophage trogocytosis. Sheri Moores, Janssen Research & Development, Spring House, PA, USA.

B04 Activity of larotrectinib in tropomyosin receptor kinase fusion lung cancer. Anna Farago, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

B05 Identifying SCLC vulnerabilities using phenotypic chemical screens. J. Povedano, University of Texas Southwestern Medical Center, Dallas, TX, USA.

B06 Time-resolved RNA-seq identifies transient gene expression changes following initial chemotherapy challenge in small cell lung cancer. David Shia, University of California Los Angeles, Los Angeles, CA, USA.

B07 Mechanisms of alectinib resistance in a leptomeningeal carcinomatosis of EML4-ALK lung cancer and its circumvention by EGFR-TKIs. Seiiji Yano, Kanazawa University, Kanazawa, Ishikawa, Japan.

B08 Impact of concurrent STK11 loss and c-MYC amplification in metastatic non-small cell lung cancer (NSCLC). Smitha Menon, Medical College of Wisconsin, Milwaukee, WI, USA.

B09 The CANOPY program: Three phase 3 studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC). Edward Garon, David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, CA, USA.


B11 Accurate detection of METex14 mutations in non-small cell lung cancer (NSCLC) with comprehensive genomic sequencing: Results from the GEOMETRY mono-1 study. Edward Garon, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

B12 FOXA2 promotes the growth of KRAS-mutant lung tumors but suppresses the growth of EGFR-mutant lung tumors in vivo. Yutaka Maeda, Cincinnati Children’s Hospital, Cincinnati, OH, USA.
Poster Session B
Monday, January 13, 2020
5:15 p.m.–7:15 p.m.

B13 Selectively targeting lung cancer with a novel small molecule that induces lethality through dual inhibition of disulfide reductases. Fraser Johnson, University of British Columbia, Vancouver, BC, Canada.

B15 COP1 E3 ligase modulates response to oncogenic MAPK pathway inhibition. Manasi Mayekar, University of California San Francisco, San Francisco, CA, USA.

B16 The ROS1 Cancer Model Project: A unique patient-driven partnership to accelerate research. Amy Moore, GO2 Foundation for Lung Cancer, San Carlos, CA, USA.

B18 Structural insight into sensitivity and resistance of RET mutants to selpercatinib (LOXO-292). Jie Wu, University of Oklahoma City Health Sciences Center, Oklahoma City, OK, USA.

B19 New potential targets of antibody-drug conjugates for small-cell lung carcinoma. Takuma Yotsumoto, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.


B22 Development of a novel serum marker for detecting small cell lung cancer by targeting a Cell Adhesion Molecule 1 (CADM1). Yoshinori Murakami, The University of Tokyo, Tokyo, Japan.

B23 Unraveling the mechanisms of small-cell lung cancer brain metastasis. Fangfei Qu, Stanford University School of Medicine, Stanford, CA, USA.

B24 The role of cigarette smoke and miR520a in pulmonary Frizzled 9 expression. Alex Smith, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

B25 Mapping the SOX2 functional network in small-cell lung cancer. Madeline Vande Kamp, Sanford Research, Sioux Falls, SD, USA.

B26 Relationship of Sox2 and Rb in tumor initiation and maintenance in small-cell lung cancer. Hannah Wollenzien, Sanford Research/University of South Dakota, Sioux Falls, SD, USA.

B28 Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer. Sang Haak Lee, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Poster Session B
Monday, January 13, 2020
5:15 p.m.–7:15 p.m.

B30 The role of SMARCA4 as an EGFR-independent mechanism of resistance to osimertinib. Fernando de Miguel, Yale University, New Haven, CT, USA.

B31 Development of multicell type organoid cultures for preclinical studies of immunotherapeutics for lung cancer. Josiah Flaming, UT Southwestern Medical Center, Dallas, TX, USA.

B32 Drug sensitivity and allele specificity of first-line osimertinib resistance EGFR mutations. Jacqueline Starrett, Yale School of Medicine, New Haven, CT, USA.

B33 Short-term exposure to REV-5901 decreases the viability of chemotherapy-resistant adherent lung cancer cells and floating tumorspheres. Juan Yakisich, Hampton University, Hampton, VA, USA.

B34 Combination therapy with Wnt pathway modulators to override chemoresistance in human lung cancer cells. Juan Yakisich, Hampton University, Hampton, VA, USA.

B35 Circulating tumor-associated cells in lung cancers are resistance-educated per previous chemotherapy treatments. Dadasaheb Akolkar, Datar Cancer Genetics Limited, Nasik, Maharashtra, India.

B36 Effects of trifluoperazine and its analog on A549 human lung cancer cells. Sang Soo Kang, Gyeongsang National University, Jinju, Gyeongnam, Korea.

B38 Serum albumin as an independent prognosis factor in patients with non-small cell lung cancer by affecting the distribution of CD8+ T cells. Lingyu Li, The First Hospital of Jilin University, Changchun, China.

B39 Cancer and palliative care in rural India (West Bengal): Experience of an NGO. Aditya Manna, Narikeldaha Prayas, East Medinipur, West Bengal, India.

B40 IGF-binding protein-mediated sensitization of EGFR-mutant NSCLC cells to osimertinib by cancer-associated fibroblast. Uwe Rix, Moffitt Cancer Center, Tampa, FL, USA.

B41 Translating lung cancer research into primary care provider training: An innovative online course. Celeste Worth, LuCa National Training Network, Louisville, KY, USA.